SCHEMBL3208495

SCHEMBL3208495

CCOC(=O)[C@@H](NC=O)C(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.39
DAGLA Q9Y4D2 1/20 0.39
MGAM O43451 1/20 0.38
GAA P10253 1/20 0.38
SI P14410 1/20 0.38
MGAM2 Q2M2H8 1/20 0.38
PKM P14618 1/20 0.36
ALDH1A1 P00352 4/20 0.36
ADH1B P00325 2/20 0.36
ADH1C P00326 2/20 0.36
ADH1A P07327 2/20 0.36
NPSR1 Q6W5P4 1/20 0.35
LMNA P02545 2/20 0.34
HSD17B10 Q99714 1/20 0.34
CA12 O43570 1/20 0.34
CA14 Q9ULX7 1/20 0.34
HPGD P15428 2/20 0.33
ALOX15 P16050 1/20 0.33
ADH4 P08319 1/20 0.33
ADH7 P40394 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22539928 1.00 CNR1 (0.39) CNR1DAGLAMGAMGAASI
SCHEMBL23256506 0.82 MGAM (0.37) MGAMGAASIMGAM2ALDH1A1
SCHEMBL19191015 0.82 CNR1 (0.36) CNR1DAGLAADH1BADH1CADH1A
SCHEMBL3201079 0.81 CA14 (0.52) CNR1DAGLAGAAADH1BADH1C
SCHEMBL8610890 0.81 CA14 (0.52) CNR1DAGLAGAAADH1BADH1C
SCHEMBL14903075 0.81 CNR1 (0.40) CNR1DAGLAALDH1A1ADH1BADH1C
SCHEMBL7060302 0.79 MGAM (0.41) CNR1DAGLAMGAMGAASI
SCHEMBL5527208 0.79 MGAM (0.41) CNR1DAGLAMGAMGAASI
SCHEMBL14903044 0.78 CNR1 (0.36) CNR1DAGLAALDH1A1ADH1BADH1C
SCHEMBL9742696 0.78 MGAM (0.33) MGAMGAASIMGAM2PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7666866-B2 Antithrombotic diamides ELI LILLY AND COMPANY (US) 2010-02-23 US disclosed
EP-1819693-B1 ANTITHROMBOTIC DIAMIDES LILLY CO ELI (US) 2009-08-26 EP disclosed
US-20090062271-A1 Antithrombotic Diamides ELI LILLY AND COMPANY (US) 2009-03-05 US disclosed
EP-1819693-A1 ANTITHROMBOTIC DIAMIDES ELI LILLY AND COMPANY (US) 2007-08-22 EP disclosed
WO-2006057868-A1 ANTITHROMBOTIC DIAMIDES ELI LILLY AND COMPANY (US) 2006-06-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062271-A1 Antithrombotic Diamides TFPI, SERPINC1, TFPI2 CNR1 3531/4885DAGLA 408/4885MGAM 1960/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.